| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | NAALAD1,Prostate-specific membrane antigen,NAALADase I,PSMA,PSM,Pteroylpoly-gamma-glutamate carboxypeptidase,Glutamate carboxypeptidase 2,N-acetylated-alpha-linked acidic dipeptidase I,Glutamate carboxypeptidase II,FOLH1,FGCP,FOLH,Folylpoly-gamma-glutamate carboxypeptidase,Folate hydrolase 1,GCPII,Membrane glutamate carboxypeptidase,Cell growth-inhibiting gene 27 protein,mGCP, |
| Clonality | |
| Form | Liquid |
| Host | |
| Immunogen | Mammalian cells - derived recombinant Human FOLH1 / PSMA (Lys44-Ala750). |
| Isotype | |
| Product Type | |
| Reactivity | |
| Storage | |
| Target |
Overview
Anti-Human FOLH1/PSMA Monoclonal Antibody (1A100) targets FOLH1 (N-acetylated-alpha-linked acidic dipeptidase I). Frequently used across ELISA, IHC, WB workflows, depending on experimental design and sample type. This antibody is suited for workflows commonly used in Molecular & Cellular Biology research.
Also known as: N-acetylated-alpha-linked acidic dipeptidase I, Cell growth-inhibiting gene 27 protein, Pteroylpoly-gamma-glutamate carboxypeptidase, Folylpoly-gamma-glutamate carboxypeptidase, Membrane glutamate carboxypeptidase, Glutamate carboxypeptidase II, Glutamate carboxypeptidase 2, Prostate-specific membrane antigen, Folate hydrolase 1, NAALADase I.
Target biology
FOLH1 (N-acetylated-alpha-linked acidic dipeptidase I) is a modification-specific target used to assess protein regulatory state rather than total protein abundance. Post-translational modification epitopes can be stimulation- and fixation-sensitive; rapid sample processing and appropriate inhibitors can help preserve signal. Common alternative names and symbols used in the literature include: Cell growth-inhibiting gene 27 protein, Pteroylpoly-gamma-glutamate carboxypeptidase, Folylpoly-gamma-glutamate carboxypeptidase, Membrane glutamate carboxypeptidase, Glutamate carboxypeptidase II, Glutamate carboxypeptidase 2, Prostate-specific membrane antigen, Folate hydrolase 1, NAALADase I, NAALAD1. Based on the annotated name/class, the target is most often associated with plasma membrane and/or intracellular membranes localization, though this can vary by model system.
How this antibody helps
As a monoclonal reagent, this antibody is designed for clone-to-clone consistency and epitope-focused recognition. For best performance, interpret signal in the context of appropriate biological controls and orthogonal readouts when available.
Antigen / immunogen context
Mammalian cells - derived recombinant Human FOLH1 / PSMA (Lys44-Ala750).
Recommended experimental notes
- Titrate the antibody to optimize signal-to-noise for your specific sample type and detection system.
- Use appropriate positive and negative controls (e.g., target-high vs target-low samples, KO/KD where available).
- For Western blotting, use fresh protease (and phosphatase, if relevant) inhibitors and confirm the primary band at the expected molecular weight; additional bands may reflect isoforms or processing.
- For IHC, optimize fixation and antigen retrieval (buffer/pH/heat) and include an isotype/secondary-only control to assess background.
- For ELISA, optimize capture/detection pairing and run a standard curve in matrix-matched diluent when possible.
Additional notes
For research use only.
For research use only. Not for diagnostic procedures.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.